Partnering

Growth strategy through partnerships

A robust growth strategy is important for a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a portfolio of products and product candidates for women’s reproductive health that can address significant unmet medical needs for millions of women worldwide.

At ObsEva, our growth strategy includes..

At ObsEva, our growth strategy includes the acquisition of additional novel clinical-stage assets that can address unmet needs for our patients. Clinical-stage assets of interest for ObsEva would meet the following criteria:

  • Women’s reproductive health medicine
  • Small chemical molecules, peptides, proteins, or mAbs
  • Development stage: close to First-In-Man up to end-of-Phase2
  • License rights: preferably global
 

Ebopiprant Collaborations

In July 2021, Obseva licensed the exclusive worldwide rights to develop, manufacturing and commercial rights to ebopiprant (OBE022) to Organon, a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with its headquarters located in Jersey City, New Jersey. Goldman Sachs acted as exclusive financial advisor to ObsEva

In November 2022, Xoma acquired the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA ,Darmstadt, Germany license Under the terms of the agreement, ObsEva is entitled to receive up to $113 million in upfront and milestone payments including $15 million which was paid at signing.

 

Get in touch for partnering

Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a potential product, please do not hesitate to send an email to the contact below briefly describing your project.

 
 





    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue